UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME doubles down on AI rails and hard assets

The biggest add is not another shiny AI software name; it’s Prologis. A +2592.3% surge in shares, lifting Prologis to $1.87B and 0.39% of the book, is a blunt statement that logistics and data-adjacent real estate are long-term infrastructure, not a trade.

On the technology side, they are sharpening the AI bet around the semiconductor stack and hyperscalers rather than broad tech beta. Microsoft, at 4.91% of the portfolio, saw a +6.1% share increase worth about $1.35B despite the position sitting roughly -10.8% below their average cost — that is classic averagedown-in-a-core-compounder behavior, not risk-off. Broadcom gets an even bolder +16.9% add of roughly $1.75B, despite the mark-to-cost math showing them deep underwater.

Alphabet’s class A shares were boosted by +10.5% (about $1.23B) and Amazon by +5.8% (about $839.4M), reinforcing a view that the hyperscale AI platforms and e-commerce/cloud rails will continue to capture outsized economics. This is a manager who wants the toll roads, not the apps.

In semis beyond the headline names, Analog Devices stands out: a +41.3% lift in shares and roughly $619.2M more capital speaks to a belief that analog, signal, and power content will be structural winners in an AI and electrification cycle. Texas Instruments (+23.4% shares) and incremental adds to Micron, AMD, Intel, Lam Research, and Nvidia extend that same theme across memory, logic, and equipment.

Outside pure tech, there is a parallel build in high-quality balance sheets. JPMorgan gets a +14.0% add (about $675.7M), Goldman Sachs +21.7% (around $383.7M), and Morgan Stanley +20.1% (roughly $303.8M). This is a coordinated tilt toward scale financial institutions that earn more from higher-for-longer rates and capital markets normalization.

Health care adds rhyme with the same playbook: durable cash-flow moats plus optionality. Johnson & Johnson (+13.6%, about $575.0M) and Eli Lilly (+8.8%, about $526.7M) signal comfort paying up for multi-decade drug franchises and obesity/oncology growth, while Abbott, Merck, AbbVie, Amgen, Gilead, and UnitedHealth all see incremental capital, albeit in smaller bites.

On the sell side, the pattern is not “abandon tech”; it’s “refine tech and de-risk cyclicals.” The largest trims by dollars are Meta, Applied Materials, Caterpillar, Tesla, Alphabet’s GOOG line, and Exxon — all reduced modestly but meaningfully as funding sources.

Meta’s stake is cut by -3.2% (about -$236.7M), a classic partial harvest after a near-doubling versus their average cost. Alphabet’s GOOG line is shaved by -1.6% (roughly -$142.3M) even as the GOOGL line is increased, suggesting a share-class rebalance rather than a change in fundamental view.

The more telling moves are in cyclicals. Caterpillar is trimmed -7.8% (about -$196.0M) despite sitting more than 300.0% above their average buy — that’s not fear of losses, it’s an explicit decision to take some industrial beta off the table. Tesla is reduced by -2.3% (around -$171.2M), easing exposure to one of the book’s higher-volatility industrials after strong gains relative to cost.

Applied Materials, down -6.5% (about -$236.2M), hints at a subtle rotation within semis: less exposure to equipment tied to cyclical wafer capex, more to diversified chip vendors like Analog Devices, Texas Instruments, and Broadcom. Exxon’s -1.1% trim (around -$29.0M) looks more like a liquidity tap in a profitable position than a fundamental call on oil, especially given the tiny move.

Taken together, the trims free capital from high-beta, late-cycle industrial and energy names plus a few fully priced growth winners, and recycle it into AI infrastructure, logistics real estate, and financials with better multi-year carry.

Sector-wise, UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME is not “de-risking tech” so much as marginally rebalancing it. Technology edges down from 59.83% to 58.66% of the top-50, but that 1.2 percentage-point slip masks a migration within tech toward core AI plumbing and away from a few overheated or cyclical names.

The more interesting moves are outside tech. Real estate jumps from 2.94% to 3.67%, driven almost entirely by the dramatic build in Prologis plus steady accumulation of Visa and Mastercard, which the data screener mislabels but functionally behave like high-margin digital toll booths on global consumption. Finance climbs from 4.82% to 5.13%, propelled by outsized adds to JPMorgan, Goldman Sachs, Morgan Stanley, Bank of America, and Wells Fargo.

Health care creeps up from 8.42% to 8.53% as they layer defensive growth via pharma, biotech, and managed care, balancing the high-octane AI bet with earnings durability. Consumer Discretionary ticks higher from 12.96% to 13.18% through adds to Amazon, Walmart, Home Depot, Costco, Netflix, McDonald’s, and TJX — a mix of digital platforms and scale physical retailers.

On the way down, Industrials slid from 4.07% to 3.68% as Caterpillar and Tesla are gently trimmed, and Energy dips from 1.10% to 1.02% with the Exxon reduction. Basic Materials and Consumer Staples hold roughly steady, with modest adds to Linde, Coca-Cola, and PepsiCo suggesting a steady hand on defensives rather than a big macro call.

The net effect: a portfolio still dominated by AI and software, but with a clear undercurrent of rotation toward hard assets (warehouses, chemicals), financial intermediaries, and resilient consumer franchises.

The through-line in this 2026-Q1 filing is a manager doubling down on the rails of the modern economy — semis, clouds, logistics, and banks — rather than its most speculative endpoints. The additions to Microsoft, Broadcom, Alphabet (GOOGL), Amazon, Analog Devices, Texas Instruments, Micron, AMD, Intel, and Lam Research all say the same thing: AI remains the core bet, but implemented through diversified, cash-generative suppliers and platforms.

Real estate moves, especially Prologis, telegraph a structural view on e-commerce, data centers, and supply-chain redesign. Coupled with larger stakes in Visa, Mastercard, and the money-center banks, the portfolio is increasingly levered to transaction volumes and nominal GDP rather than narrow style factors.

On the risk side, trims in Caterpillar, Tesla, Meta, Applied Materials, and Exxon show a willingness to recycle winners and edge down cyclical exposure after a powerful three-year run (the weighted 3-year annualized return sits at 37.25%, with a 158.55% cumulative gain). Health care adds to Eli Lilly, Johnson & Johnson, AbbVie, Merck, Amgen, Gilead, and UnitedHealth provide a ballast of regulated, high-return franchises with embedded innovation.

Looking forward, unless the AI thesis breaks, don’t expect a wholesale rotation out of tech — the fund has simply upgraded its exposure toward what it sees as durable toll collectors. The rising allocation to real assets and financials suggests they are positioning for a world of still-elevated rates, ongoing capex in data and logistics, and steady consumer spend rather than a sharp macro downturn.

If anything, this quarter’s moves suggest that future tweaks will come from within sectors — swapping cyclicals for structurals and beta for moats — rather than big top-down sector swings.